Terms: = Colorectal cancer AND PPFIBP1, L2, 8496, ENSG00000110841, hSGT2, hSgt2p
110 results:
1. CCR5 and CCL5 in metastatic colorectal cancer.
Schlechter BL; Stebbing J
J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38719543
[TBL] [Abstract] [Full Text] [Related]
2. Identification and Validation of the Glycolysis and Immune-related Gene Signature for Prognosis in colorectal cancer.
Jiang M; Liu Y; Xu J; Xu Z; Ye T; Li S; Jiang C
Anticancer Res; 2024 Jan; 44(1):117-131. PubMed ID: 38159970
[TBL] [Abstract] [Full Text] [Related]
3. Clinical significance of programmed cell death-ligand expression in small bowel adenocarcinoma is determined by the tumor microenvironment.
Hoshimoto A; Tatsuguchi A; Hamakubo R; Nishimoto T; Omori J; Akimoto N; Tanaka S; Fujimori S; Hatori T; Shimizu A; Iwakiri K
World J Gastroenterol; 2023 Oct; 29(40):5566-5581. PubMed ID: 37970475
[TBL] [Abstract] [Full Text] [Related]
4. Cholinergic signaling influences the expression of immune checkpoint inhibitors, PD-L1 and PD-L2, and tumor hallmarks in human colorectal cancer tissues and cell lines.
Kuol N; Godlewski J; Kmiec Z; Vogrin S; Fraser S; Apostolopoulos V; Nurgali K
BMC Cancer; 2023 Oct; 23(1):971. PubMed ID: 37828429
[TBL] [Abstract] [Full Text] [Related]
5. GSK-3 Inhibitor Elraglusib Enhances Tumor-Infiltrating Immune Cell Activation in Tumor Biopsies and Synergizes with Anti-PD-L1 in a Murine Model of colorectal cancer.
Huntington KE; Louie AD; Srinivasan PR; Schorl C; Lu S; Silverberg D; Newhouse D; Wu Z; Zhou L; Borden BA; Giles FJ; Dooner M; Carneiro BA; El-Deiry WS
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37446056
[TBL] [Abstract] [Full Text] [Related]
6. Pan-cancer analysis identifies PD-L2 as a tumor promotor in the tumor microenvironment.
Lv J; Jiang Z; Yuan J; Zhuang M; Guan X; Liu H; Yin Y; Ma Y; Liu Z; Wang H; Wang X
Front Immunol; 2023; 14():1093716. PubMed ID: 37006239
[TBL] [Abstract] [Full Text] [Related]
7. Promise of dostarlimab in cancer therapy: Advancements and cross-talk considerations.
Babar Q; Saeed A; Murugappan S; Dhumal D; Tabish T; Thorat ND
Drug Discov Today; 2023 Jun; 28(6):103577. PubMed ID: 37004983
[TBL] [Abstract] [Full Text] [Related]
8. APC mutation correlated with poor response of immunotherapy in colon cancer.
Li B; Zhang G; Xu X
BMC Gastroenterol; 2023 Mar; 23(1):95. PubMed ID: 36977982
[TBL] [Abstract] [Full Text] [Related]
9. PD-L1 and PD-L2 expression in colorectal cancer.
Zeynep O; Funda C; Evrim Y; Deniz A; Bülent Y; Fatih YN
Indian J Pathol Microbiol; 2023; 66(1):31-37. PubMed ID: 36656207
[TBL] [Abstract] [Full Text] [Related]
10. Pucotenlimab: First Approval.
Dhillon S
Drugs; 2022 Oct; 82(15):1557-1564. PubMed ID: 36308601
[TBL] [Abstract] [Full Text] [Related]
11. Novel chiral Schiff base Palladium(II), Nickel(II), Copper(II) and Iron(II) complexes: Synthesis, characterization, anticancer activity and molecular docking studies.
Basaran E; Gamze Sogukomerogullari H; Cakmak R; Akkoc S; Taskin-Tok T; Köse A
Bioorg Chem; 2022 Dec; 129():106176. PubMed ID: 36209564
[TBL] [Abstract] [Full Text] [Related]
12. High MICAL-L2 expression and its role in the prognosis of colon adenocarcinoma.
Yang Y; Ye F; Xia T; Wang Q; Zhang Y; Du J
BMC Cancer; 2022 May; 22(1):487. PubMed ID: 35501725
[TBL] [Abstract] [Full Text] [Related]
13. Abdominal adipose tissue quantification and distribution with CT: prognostic value for surgical and oncological outcome in patients with rectal cancer.
Pacquelet B; Morello R; Pelage JP; Eid Y; Lebreton G; Alves A; Fohlen A
Eur Radiol; 2022 Sep; 32(9):6258-6269. PubMed ID: 35348868
[TBL] [Abstract] [Full Text] [Related]
14. Cathepsin V: Molecular characteristics and significance in health and disease.
Lecaille F; Chazeirat T; Saidi A; Lalmanach G
Mol Aspects Med; 2022 Dec; 88():101086. PubMed ID: 35305807
[TBL] [Abstract] [Full Text] [Related]
15. Second-line treatment after docetaxel, cisplatin and 5-fluorouracil in metastatic squamous cell carcinomas of the anus. Pooled analysis of prospective Epitopes-HPV01 and Epitopes-HPV02 studies.
Stouvenot M; Meurisse A; Saint A; Buecher B; André T; Samalin E; Jary M; El Hajbi F; Baba-Hamed N; Pernot S; Kaminsky MC; Bouché O; Desrame J; Zoubir M; Smith D; Ghiringhelli F; Parzy A; de la Fouchardiere C; Almotlak H; Vienot A; Jacquin M; Taieb J; Nguyen T; Vernerey D; Borg C; Kim S
Eur J Cancer; 2022 Feb; 162():138-147. PubMed ID: 34995900
[TBL] [Abstract] [Full Text] [Related]
16. colorectal cancer-Associated Immune Exhaustion Involves T and B Lymphocytes and Conventional NK Cells and Correlates With a Shorter Overall Survival.
Sorrentino C; D'Antonio L; Fieni C; Ciummo SL; Di Carlo E
Front Immunol; 2021; 12():778329. PubMed ID: 34975867
[TBL] [Abstract] [Full Text] [Related]
17. Periodontitis, Helicobacter pylori infection, and gastrointestinal tract cancer mortality.
Sung CE; Lin FG; Huang RY; Fang WH; Cheng WC; Tsai YC; Chen WL
J Clin Periodontol; 2022 Mar; 49(3):210-220. PubMed ID: 34961943
[TBL] [Abstract] [Full Text] [Related]
18. Contribution of endothelial cell-derived transcriptomes to the colon cancer based on bioinformatics analysis.
Wang J; Uddin MN; Akter R; Wu Y
Math Biosci Eng; 2021 Aug; 18(6):7280-7300. PubMed ID: 34814249
[TBL] [Abstract] [Full Text] [Related]
19. Response to Pembrolizumab in Advanced Anal Squamous Cell Carcinoma With High TMB and PD-L1 and PD-L2 Amplification.
Tostes FT; Fernandes I; Segatelli V; Callegaro D; Carmagnani Pestana R
Clin Colorectal Cancer; 2021 Dec; 20(4):350-353. PubMed ID: 34154923
[TBL] [Abstract] [Full Text] [Related]
20. PD-1 derived CA-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efficacy.
Sasikumar PG; Sudarshan NS; Adurthi S; Ramachandra RK; Samiulla DS; Lakshminarasimhan A; Ramanathan A; Chandrasekhar T; Dhudashiya AA; Talapati SR; Gowda N; Palakolanu S; Mani J; Srinivasrao B; Joseph D; Kumar N; Nair R; Atreya HS; Gowda N; Ramachandra M
Commun Biol; 2021 Jun; 4(1):699. PubMed ID: 34103659
[TBL] [Abstract] [Full Text] [Related]
[Next]
